Search Results - "Krishnaswami, Sriram"

Tofacitinib versus Methotrexate in Rheumatoid Arthritis by Lee, Eun Bong, Fleischmann, Roy, Hall, Stephen, Wilkinson, Bethanie, Bradley, John D, Gruben, David, Koncz, Tamas, Krishnaswami, Sriram, Wallenstein, Gene V, Zang, Chuanbo, Zwillich, Samuel H, van Vollenhoven, Ronald F

“…In patients with rheumatoid arthritis, tofacitinib was associated with greater reductions in signs and symptoms than methotrexate. Herpes zoster infections and…”
Get full text

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis by van Vollenhoven, Ronald F, Fleischmann, Roy, Cohen, Stanley, Lee, Eun Bong, García Meijide, Juan A, Wagner, Sylke, Forejtova, Sarka, Zwillich, Samuel H, Gruben, David, Koncz, Tamas, Wallenstein, Gene V, Krishnaswami, Sriram, Bradley, John D, Wilkinson, Bethanie

“…In this trial of patients with rheumatoid arthritis who were on stable doses of methotrexate, tofacitinib, a novel oral Janus kinase inhibitor, was more…”
Get full text

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial by Burmester, Gerd R, Prof, Blanco, Ricardo, MD, Charles-Schoeman, Christina, MD, Wollenhaupt, Jürgen, Prof, Zerbini, Cristiano, MD, Benda, Birgitta, MD, Gruben, David, PhD, Wallenstein, Gene, PhD, Krishnaswami, Sriram, PhD, Zwillich, Samuel H, MD, Koncz, Tamas, MD, Soma, Koshika, MD, Bradley, John, MD, Mebus, Charles, PhD

“…Summary Background Rheumatoid arthritis is a heterogeneous chronic disease, and no therapeutic agent has been identified which is universally and persistently…”
Get full text

The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans by Dowty, Martin E, Lin, Jinyan, Ryder, Tim F, Wang, Weiwei, Walker, Gregory S, Vaz, Alfin, Chan, Gary L, Krishnaswami, Sriram, Prakash, Chandra

“…Tofacitinib is a novel, oral Janus kinase inhibitor. The objectives of this study were to summarize the pharmacokinetics and metabolism of tofacitinib in…”
Get full text

Role of pharmacometrics and systems pharmacology in facilitating efficient dose optimization in oncology by Jayachandran, Priya, Desikan, Rajat, Krishnaswami, Sriram, Hennig, Stefanie

“…The articles in the themed issue can be broadly classified into three categories: (1) continuation of core/traditional quantitative clinical pharmacology…”
Get full text

Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes by Riese, Richard J., MD, PhD, Krishnaswami, Sriram, PhD, Kremer, Joel, MD

“…CP-690,550 is an orally active and selective inhibitor of the janus kinase (JAK) molecules. The molecular pathways through which the JAK moieties function are…”
Get full text

Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study by Ruperto, Nicolino, Brunner, Hermine I, Zuber, Zbigniew, Tzaribachev, Nikolay, Kingsbury, Daniel J, Foeldvari, Ivan, Horneff, Gerd, Smolewska, Elzbieta, Vehe, Richard K, Hazra, Anasuya, Wang, Rong, Mebus, Charles A, Alvey, Christine, Lamba, Manisha, Krishnaswami, Sriram, Stock, Thomas C, Wang, Min, Suehiro, Ricardo, Martini, Alberto, Lovell, Daniel J

“…Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease and a leading cause of childhood disability. The objective of this study was…”
Get full text

CPT: Pharmacometrics & Systems Pharmacology – Inception, Maturation, and Future Vision by Rowland Yeo, Karen, Hennig, Stefanie, Krishnaswami, Sriram, Strydom, Natasha, Ayyar, Vivaswath S., French, Jonathan, Sinha, Vikram, Sobie, Eric, Zhao, Ping, Friberg, Lena E., Mentré, France

“…PSP was launched in September 2012, as the second journal of American Society for Clinical Pharmacology and Therapeutics (ASCPT), with the first being Clinical…”
Get full text

Analgesic efficacy of celecoxib in postoperative oral surgery pain: A single-dose, two-center, randomized, double-blind, active- and placebo-controlled study by Cheung, Raymond, PhD, Krishnaswami, Sriram, PhD, Kowalski, Ken, MS

“…Abstract Background: Celecoxib 200 mg has been reported to reduce pain following dental extraction but to offer poorer pain relief than active comparators…”
Get full text

Evaluation of the effect of fluconazole and ketoconazole on the pharmacokinetics of tofacitinib in healthy adult subjects by Gupta, Pankaj, Chow, Vincent, Wang, Ronnie, Kaplan, Irina, Chan, Gary, Alvey, Christine, Ni, Grace, Ndongo, Marie-Noella, LaBadie, Robert R., Krishnaswami, Sriram

“…Tofacitinib is a novel, oral JAK inhibitor that is being investigated as a targeted immunomodulator. Tofacitinib is predominantly metabolized by cytochrome…”
Get full text

A Prospective Study Comparing Celecoxib with Naproxen in Children with Juvenile Rheumatoid Arthritis by FOELDVARI, Ivan, SZER, Ilona S, ZEMEL, Lawrence S, LOVELL, Daniel J, GIANNINI, Edward H, ROBBINS, Jeffery L, WEST, Christine R, STEIDLE, Gina, KRISHNASWAMI, Sriram, BLOOM, Bradley J

“…Objective To compare the efficacy and safety of celecoxib and naproxen in children with juvenile rheumatoid arthritis (JRA). Methods In this multicenter,…”
Get full text

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis by Winthrop, Kevin L., Yamanaka, Hisashi, Valdez, Hernan, Mortensen, Eric, Chew, Robert, Krishnaswami, Sriram, Kawabata, Thomas, Riese, Richard

“…Objective Patients with rheumatoid arthritis (RA) are at increased risk for herpes zoster (HZ) (i.e., shingles). The aim of this study was to determine whether…”
Get full text

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: A Randomized Trial by KREMER, Joel, LI, Zhan-Guo, ZWILLICH, Samuel H, KONCZ, Tamas, RIESE, Richard, BRADLEY, John, HALL, Stephen, FLEISCHMANN, Roy, GENOVESE, Mark, MARTIN-MOLA, Emilio, ISAACS, John D, GRUBEN, David, WALLENSTEIN, Gene, KRISHNASWAMI, Sriram

“…Many patients with rheumatoid arthritis (RA) do not achieve adequate and safe responses with disease-modifying antirheumatic drugs (DMARDs). Tofacitinib is a…”
Get full text

A sensitive LC–MS/MS method for the quantification of fluticasone propionate in human plasma by Krishnaswami, Sriram, Möllmann, Helmut, Derendorf, Hartmut, Hochhaus, Günther

“…A sensitive and selective LC–(APCI) MS/MS method capable of quantifying fluticasone propionate (FP) at levels down to 10 pg ml −1 in human plasma is reported…”
Get full text

Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study by van der Heijde, Désirée, Tanaka, Yoshiya, Fleischmann, Roy, Keystone, Edward, Kremer, Joel, Zerbini, Cristiano, Cardiel, Mario H., Cohen, Stanley, Nash, Peter, Song, Yeong‐Wook, Tegzová, Dana, Wyman, Bradley T., Gruben, David, Benda, Birgitta, Wallenstein, Gene, Krishnaswami, Sriram, Zwillich, Samuel H., Bradley, John D., Connell, Carol A.

“…Objective The purpose of this 24‐month phase III study was to examine structural preservation with tofacitinib in patients with rheumatoid arthritis (RA) with…”
Get full text

The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis by Hodge, Jennifer A, Kawabata, Thomas T, Krishnaswami, Sriram, Clark, James D, Telliez, Jean-Baptiste, Dowty, Martin E, Menon, Sujatha, Lamba, Manisha, Zwillich, Samuel

“…Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterised by infiltration of immune cells into the affected synovium, release of…”
Get full text

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial by Fleischmann, Roy, Prof, Mysler, Eduardo, MD, Hall, Stephen, MD, Kivitz, Alan J, MD, Moots, Robert J, Prof, Luo, Zhen, PhD, DeMasi, Ryan, MD, Soma, Koshika, MD, Zhang, Richard, PhD, Takiya, Liza, PharmD, Tatulych, Svitlana, MD, Mojcik, Christopher, MD, Krishnaswami, Sriram, PhD, Menon, Sujatha, PhD, Smolen, Josef S, Prof

“…Summary Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy…”
Get full text

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib by Tse, Susanna, Dowty, Martin E., Menon, Sujatha, Gupta, Pankaj, Krishnaswami, Sriram

“…Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is eliminated via…”
Get full text

Model‐Based Comparison of Dose‐Response Profiles of Tofacitinib in Japanese Versus Western Rheumatoid Arthritis Patients by Suzuki, Misaki, Shoji, Satoshi, Miyoshi, So, Krishnaswami, Sriram

“…Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The aim of this analysis was to characterize the relationship…”
Get full text

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials by Strand, Vibeke, Ahadieh, Sima, French, Jonathan, Geier, Jamie, Krishnaswami, Sriram, Menon, Sujatha, Checchio, Tina, Tensfeldt, Thomas G, Hoffman, Elaine, Riese, Richard, Boy, Mary, Gómez-Reino, Juan J

“…Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib modulates the signaling of cytokines that are…”
Get full text